1 / 22

BROMI Variations · Launch Meeting The Cumberland Hotel, London

Explore the BROMI Variations program that aims to simplify pharmaceutical regulatory processes, reduce administrative burdens, and enhance efficiency in approval times. Learn about the 3-tier model, self-certification, and expedited processing options for different change categories. Discover how the pilot program benefited participating companies and the common errors to avoid in application submissions.

gardner
Download Presentation

BROMI Variations · Launch Meeting The Cumberland Hotel, London

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BROMI Variations · Launch Meeting The Cumberland Hotel, London Anne Ambrose 8th May 2008

  2. BROMI - Variations • Variations – High Volume work stream • Approx 22,000 variation applications received annually in UK. • 50% Type IA • 80% National • Risk based approach to assessment. • Reduction in administrative burden. • Predictable approval times • Delivery of new ways of working.

  3. Current Regulatory Framework • Regulation EC 1084/2003 – Mutual Recognition • Regulation EC 1085/2003 – Centralised Procedure • UK – Follows principles of Regulations EC1084/2003 and EU Best Practice Guidance

  4. BROMI Concepts

  5. Variations – Proposal for 3-tier modelfor certain categories of change – Based on MR procedures Scientific Validation (IA) Self Certification 30 Day Assessment (IB) Type IA Type II Type IB

  6. BROMI - Variations • Choice of Categories for Self Certification or Expedited Processing: • Review of National applications determined by MHRA. • Categories with low number of invalidation/refusals. • Changes that had become Type II with introduction of 1084/2003EC.

  7. Variations – 3 tier model • Self Certification BROMI – ‘Tell and do’ • - Approx 80% of current Type IA; • - Approx 7000 per annum in UK • Type IA BROMI – 14 day scientific validation • Type IB BROMI – 30 day assessment procedure

  8. BROMI -Variations • How would the 3-tier model help my company? • Change in name and address of MA Holder (same legal entity) • Current – Type IA with 14 Day validation procedure • BROMI – Self Certified change that can be implemented immediately

  9. Minor Change in the Manufacture of the Active Ingredient • Current – Type IB 30-Day assessment procedure • BROMI – Under certain conditions Type IA 14-Day validation • Replacement or addition of a manufacturer for a sterile product • Current – Type II 90-Day assessment procedure • BROMI – Type IB 30-Day assessment procedure

  10. BROMI Variations Pilot • Initial Phase 1st February – 31st July 2007 • Limited Number of Companies (11 company groups) • Use of Sentinel Portal • Audit • Evaluation • Pilot extended to 31st January 2008

  11. BROMI Variations Pilot – Participating Companies • Galpharm • GSK • Lundbeck • Organon • Pliva • Pfizer • Reckitt Benckiser • Rosemont • Sanofi- Aventis • Teva • Wockhardt

  12. Procedures for Submitting BROMI Notifications • Self Certification: • Acknowledgment issued as MAH submits application through Sentinel Portal • Sentinel/Rama records updated in 14-Days and formal acknowledgment letter issued

  13. BROMI Variations Applications Submitted • In total 609 BROMI Variations received during the 6 month pilot • BROMI Self Certification = 518 • BROMI Type IA = 74 • BROMI Type IB = 17

  14. Applications Submitted

  15. BROMI Self Certification

  16. Audit Outcome • Common Mistakes on applications - Omission of Declaration Form - - Omission of updated PL and/or label - Inadequate QP Declarations - Multiple Ph Eur CEPs in a single notification • Most common categories for error - Changes to Tablet or Capsule Markings - Change to Batch Release and QC Arrangements – QP Declarations - Manufacturer of active, – documentation - Change in company name/address

  17. BROMI Variations Pilot • Company Questionnaire • Approval time – great advantage. • Admin burden – further reduction required. • Guidance and Procedure – further simplification required. • Pilot extended to 31st January 2008

  18. Extension of Pilot • Categories reviewed – Change #8. Batch release removed. • Simplify guidance. • Reduce Documentation Requirements. • Improved audit

  19. Applications Received Feb 07 – Jan 08 Approx 1,500 applications received in total 900 Self-Certified

  20. BROMI – Variations • Final evaluation of pilot • Full Roll-out to MAHs. • National Applications • Portal Applications • Next Steps • Further amendments to Sentinel process and letters issued

  21. Next Steps • Revision of EU Variation Regulations • Two categories of Type IA notification • Those requiring immediate notification • Those that can be included in an annual update • Downgrading of variations that have received a scientific opinion

  22. Do you have any further suggestions? • BROMI@mhra.gsi.gov.uk

More Related